Please select the option that best describes you:
Topics:
Medical Oncology
What are your top takeaways in GU Cancers from ASCO 2024?
Answer from: Medical Oncologist at Academic Institution
In terms of practice-changing/informing datasets newly presented at ASCO 2024, here are my top 5:
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy. LBA12004, ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Focusing on bladder cancer only, I suggest these below:
@Shilpa Gupta: EV-302 PRO/QoL data
@Daniel P. Petrylak: Dose exposure and association with ORR with EV monotherapy
@Matt D. Galsky: CheckMate 901 - characterization of patients with complete response
Antonio Cigli...
Answer from: Medical Oncologist at Community Practice
My top 3 for prostate cancer were:
Abstract 5010: JNJ-69086420 for mCRPC
Abstract 5011: ARV-766 for mCRPC
Abstract 5012: Tarlatamab for Neuroendocrine Prostate Cancer
Answer from: Medical Oncologist at Academic Institution
Abstract 4503, Dr. @Daniel P. Petrylak's review of dose received and duration of therapy for EV/pembro in metastatic urothelial ca reassured me that patients do well even with reduced dosing of EV.
Dr. @Wenxin Xu's discussion of KIM-1 in response to Dr. Albiges' post hoc analysis of KIM-1 in IMmo...
Answer from: Radiation Oncologist at Community Practice
PSMAfore presented previously showed (177Lu-PSMA-617) prolonged radiographic progression-free survival vs change of androgen receptor pathway inhibitor (ARPI) in taxane-naïve patients with metastatic castration-resistant prostate cancer. At ASCO, data presented showed 177Lu-PSMA-617 delayed tim...
Answer from: Medical Oncologist at Academic Institution
KEYNOTE-361 trial, Abstract 4518 - Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.
-- This is particularly important a...